Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - besremi
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp65cdaa8e626b314e9a691e6afef8bf66
identifier: http://ema.europa.eu/identifier
/EU/1/18/1352/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Besremi 250 micrograms/0.5 mL solution for injection in pre-filled pen
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-65cdaa8e626b314e9a691e6afef8bf66
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/18/1352/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - besremi
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Besremi contains the active substance ropeginterferon alfa-2b, which belongs to the class of medicines called interferons. Interferons are produced by your immune system to block the growth of cancer cells.
Besremi is used as monotherapy for the treatment of polycythaemia vera in adults. Polycythaemia vera is a type of cancer in which the bone marrow produces too many red blood cells, white blood cells and platelets (cells that help the blood to clot).
Do not use Besremi
Warnings and precautions Talk to your doctor before using Besremi:
Once you have started Besremi treatment, talk to your doctor:
Dental and gum disorders, which may lead to loss of teeth, can occur with interferon medicines. In addition, dry mouth could damage teeth and the lining of the mouth during long-term treatment with Besremi. You should brush your teeth thoroughly twice daily and have regular dental checks.
It will need a certain time to reach your individual optimal dose of Besremi. Your doctor will decide if it is necessary to treat you with another medicine for an early reduction of your blood cell number to prevent blood clots and bleeding.
Children and adolescents Do not give this medicine to children and adolescents because no information is available on the use of Besremi in this age group.
Other medicines and Besremi Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Do not use Besremi if you are taking telbivudine (for treating hepatitis B) since the combination of these medicines increases the risk of peripheral neuropathy (numbness, tingling, or burning sensations in the arms and legs). Tell your doctor if you are being treated with telbivudine.
Tell your doctor especially if you are taking any of the following medicines:
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Pregnancy The effect of Besremi during pregnancy is not known. The use of Besremi is not recommended during pregnancy. If you are a woman of childbearing potential, your doctor will discuss with you if effective birth control should be used during your treatment with Besremi.
Breast-feeding It is not known if Besremi is present in breast milk. Your doctor will help you decide if you have to stop breast-feeding when you are using this medicine.
Driving and using machines Do not drive or use machines if you feel dizzy, sleepy or confused while using Besremi.
Besremi contains benzyl alcohol This medicine contains 5 mg benzyl alcohol in each 0.5 mL. Benzyl alcohol may cause allergic reactions. Ask your doctor or pharmacist for advice:
Besremi contains sodium This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially sodium- free .
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The dose will be set individually for you by your doctor for your condition. The usual starting dose of Besremi is 100 microgram every 2 weeks. Your doctor will then increase your dose stepwise and may adjust your dose during treatment. Your doctor will reduce your starting dose to 50 micrograms if you have severe kidney problems.
This medicine is for subcutaneous use which means that it is injected in the tissue under your skin. It should not be injected into an area of the body where the skin is irritated, reddened, bruised, infected, or scarred. If you are injecting this medicine yourself, you will get clear instructions on how to prepare and inject it. To prevent passing on infectious diseases, you should never share Besremi pre-filled pen with anyone else, even when the needle is changed.
Details on how to prepare and inject Besremi are given in the Instructions for Use. Read them before you start using Besremi.
If you use more Besremi than you should Tell your doctor as soon as possible.
If you forget to use Besremi You should inject the dose as soon as you remember. However, if more than 2 days have passed since you missed the dose, leave out the dose and inject the next dose when it is due. Do not inject a double dose to make up for a forgotten dose. Check with your doctor or pharmacist if you are not sure.
If you stop using Besremi Do not stop using Besremi before you have talked to your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor immediately if you notice any of the following serious side effects during your treatment with Besremi:
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Very rare side effects (may affect up to 1 in 10,000 people):
Side effects with frequency not known (cannot be estimated from the available data):
Other side effects
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Very rare side effects (may affect up to 1 in 10,000 people):
Side effects with frequency not known (cannot be estimated from the available data):
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and the outer carton after EXP . The expiry date refers to the last day of that month.
Store in a refrigerator (2 C 8 C). Do not freeze. Keep the pre-filled pen in the outer carton in order to protect from light.
Once opened, the pre-filled pen may be stored for a maximum of 30 days in the refrigerator (2 C - 8 C) when stored with the pen cap on and kept in the outer carton in order to protect from light.
Do not use this medicine if you notice that the pre-filled pen appears damaged, the solution is cloudy, has particles or flakes, or has any colour other than colourless to slightly yellow.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Besremi contains
Each pre-filled pen of 0.5 mL solution contains 250 micrograms of ropeginterferon alfa-2b as measured on a protein basis, corresponding to 500 micrograms/mL.
What Besremi looks like and contents of the pack Besremi is presented as a solution for injection (injection) in a pre-filled pen. Each pre-filled pen contains 0.5 mL of solution. It is available in packs containing:
Marketing Authorisation Holder and Manufacturer AOP Orphan Pharmaceuticals GmbH Leopold-Ungar-Platz 2 1190 Vienna Austria
This leaflet was last revised in .
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-65cdaa8e626b314e9a691e6afef8bf66
Resource Composition:
Generated Narrative: Composition composition-en-65cdaa8e626b314e9a691e6afef8bf66
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/18/1352/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - besremi
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp65cdaa8e626b314e9a691e6afef8bf66
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp65cdaa8e626b314e9a691e6afef8bf66
identifier:
http://ema.europa.eu/identifier
/EU/1/18/1352/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Besremi 250 micrograms/0.5 mL solution for injection in pre-filled pen
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en